This Article Full Text Full Text (PDF) All Versions of this Article: 145/4/1656    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grover, G. J. Articles by Scanlan, T. S. Search for Related Content PubMed PubMed Citation Articles by Grover, G. J. Articles by Scanlan, T. S.

Effects of the Thyroid Hormone Receptor Agonist GC-1 on Metabolic Rate and Cholesterol in Rats and Primates: Selective Actions Relative to 3,5,3'-Triiodo-L-Thyronine

Metabolic and Cardiovascular Drug Discovery (G.J.G., D.M.E., P.G.S., B.C.B.), Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey 08534; and Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology (N.-H.N., T.S.S.) and the Metabolic Research Unit (J.D.B.), University of California, San Francisco, San Francisco, California 94143

Address all correspondence and requests for reprints to: Gary J. Grover, Ph.D., Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey 08534. E-mail: groverg{at}bms.com.

Current drug therapies for obesity are ineffective, and existing treatments for lipid disorders can be further improved. Thyroid hormones affect both conditions, although currently available nonselective thyromimetics are not clinically useful for such treatment due to cardiac side effects. Recent studies suggest that thyroid hormone receptor subtype ß (TRß) selective agonists have a profile in which cholesterol can be reduced with minimal tachycardia. The purpose of this study was to determine whether modest (5–10%) increases in metabolic rate could also be observed with minimal tachycardia after TRß stimulation. For these studies, the TRß selective agonist, GC-1, was used to assess selectivity for lipid-lowering and metabolic rate changes relative to tachycardia. Studies in cholesterol-fed rats (7 d treatment) showed that GC-1 reduced cholesterol (ED₅₀ = 190 nmol/kg·d) approximately 30 times more potently than it induced tachycardia (ED₁₅ = 5451 nmol/kg·d). T₃ showed no potency difference between cholesterol lowering and tachycardia. GC-1 showed approximately 10-fold selectivity for increasing metabolic rate (ED₅ = 477 nmol/kg·d) relative to tachycardia compared with T₃, which showed no selectivity. In cynomolgus monkeys treated for 7 d, significant cholesterol-lowering and lipoprotein (a) reduction was noted for both T₃ and GC-1, whereas no tachycardia was observed for GC-1, unlike T₃. T₃ and GC-1 caused a significant (4%) reduction in body weight in these animals. Therefore, selective TRß activation may be a potentially usefully treatment for obesity and reduction of low density lipoprotein cholesterol and reduction of the atherogenic risk factor lipoprotein (a).

This article has been cited by other articles:

				A. Perra, G. Simbula, M. Simbula, M. Pibiri, M. A. Kowalik, P. Sulas, M. T. Cocco, G. M. Ledda-Columbano, and A. Columbano Thyroid hormone (T3) and TR{beta} agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats FASEB J, August 1, 2008; 22(8): 2981 - 2989. [Abstract] [Full Text] [PDF]

				A. Berkenstam, J. Kristensen, K. Mellstrom, B. Carlsson, J. Malm, S. Rehnmark, N. Garg, C. M. Andersson, M. Rudling, F. Sjoberg, et al. From the Cover: The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans PNAS, January 15, 2008; 105(2): 663 - 667. [Abstract] [Full Text] [PDF]

				S. M. Grundy Thyroid mimetic as an option for lowering low-density lipoprotein PNAS, January 15, 2008; 105(2): 409 - 410. [Full Text] [PDF]

				M. D. Erion, E. E. Cable, B. R. Ito, H. Jiang, J. M. Fujitaki, P. D. Finn, B.-H. Zhang, J. Hou, S. H. Boyer, P. D. van Poelje, et al. From the Cover: Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index PNAS, September 25, 2007; 104(39): 15490 - 15495. [Abstract] [Full Text] [PDF]

				G. J. Grover, C. Dunn, N.-H. Nguyen, J. Boulet, G. Dong, J. Domogauer, P. Barbounis, and T. S. Scanlan Pharmacological Profile of the Thyroid Hormone Receptor Antagonist NH3 in Rats J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 385 - 390. [Abstract] [Full Text] [PDF]

				C. M Villicev, F. R S Freitas, M. S Aoki, C. Taffarel, T. S Scanlan, A. S Moriscot, M. O Ribeiro, A. C Bianco, and C. H A Gouveia Thyroid hormone receptor {beta}-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats J. Endocrinol., April 1, 2007; 193(1): 21 - 29. [Abstract] [Full Text] [PDF]

				F. Flamant, K. Gauthier, and J. Samarut Thyroid Hormones Signaling Is Getting More Complex: STORMs Are Coming Mol. Endocrinol., February 1, 2007; 21(2): 321 - 333. [Abstract] [Full Text] [PDF]

				X. Ding, K. Lichti, I. Kim, F. J. Gonzalez, and J. L. Staudinger Regulation of Constitutive Androstane Receptor and Its Target Genes by Fasting, cAMP, Hepatocyte Nuclear Factor {alpha}, and the Coactivator Peroxisome Proliferator-activated Receptor {gamma} Coactivator-1{alpha} J. Biol. Chem., September 8, 2006; 281(36): 26540 - 26551. [Abstract] [Full Text] [PDF]

				A. Columbano, M. Pibiri, M. Deidda, C. Cossu, T. S. Scanlan, G. Chiellini, S. Muntoni, and G. M. Ledda-Columbano The Thyroid Hormone Receptor-{beta} Agonist GC-1 Induces Cell Proliferation in Rat Liver and Pancreas Endocrinology, July 1, 2006; 147(7): 3211 - 3218. [Abstract] [Full Text] [PDF]

				L. A. Arnold, E. Estebanez-Perpina, M. Togashi, N. Jouravel, A. Shelat, A. C. McReynolds, E. Mar, P. Nguyen, J. D. Baxter, R. J. Fletterick, et al. Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators J. Biol. Chem., December 30, 2005; 280(52): 43048 - 43055. [Abstract] [Full Text] [PDF]

				K Boelaert and J A Franklyn Thyroid hormone in health and disease J. Endocrinol., October 1, 2005; 187(1): 1 - 15. [Abstract] [Full Text] [PDF]

				L. Martinez, M. T. Sonoda, P. Webb, J. D. Baxter, M. S. Skaf, and I. Polikarpov Molecular Dynamics Simulations Reveal Multiple Pathways of Ligand Dissociation from Thyroid Hormone Receptors Biophys. J., September 1, 2005; 89(3): 2011 - 2023. [Abstract] [Full Text] [PDF]

				X. Prieur, T. Huby, H. Coste, F. G. Schaap, M. J. Chapman, and J. C. Rodriguez Thyroid Hormone Regulates the Hypotriglyceridemic Gene APOA5 J. Biol. Chem., July 29, 2005; 280(30): 27533 - 27543. [Abstract] [Full Text] [PDF]

				L. Johansson, M. Rudling, T. S. Scanlan, T. Lundasen, P. Webb, J. Baxter, B. Angelin, and P. Parini Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice PNAS, July 19, 2005; 102(29): 10297 - 10302. [Abstract] [Full Text] [PDF]